Abstract:Introduction: Gastrointestinal stromal tumor (GIST) is the most common human sarcoma and is typically driven by a single mutation in the Kit receptor. While highly effective, tyrosine kinase inhibitors like imatinib are not curative. The natural ligand for the Kit receptor is Kit Ligand (KitL), which exists in both soluble and membrane-bound forms. We sought to determine the role of KitL in the oncogenic Kit signaling of GIST. Methods: KitV558Δ/+ mice, which spontaneously develop an intestinal GIST, were treated with imatinib or vehicle for 1 week, and sorted non-immune (CD45-) cells from tumors were submitted for single-cell RNA sequencing (n=3/group). GIST T1 cells were treated with KitL with or without imatinib and oncogenic Kit signaling was evaluated. KitV558Δ/+ mice were crossed with various KitL mutant and inducible models and tumor weights were measured (n=3-4/group). Human GISTs were stained for KitL expression by IHC, and an existing bulk RNA sequencing human GIST dataset with matched human serum was analyzed. Results: Unsupervised clustering revealed endothelial, smooth muscle, and tumor cells had high expression of KitL RNA in untreated tumors from KitV558Δ/+ mice. Imatinib therapy increased KitL RNA in all 3 cell types, suggesting that extra-tumoral KitL expression is dependent on oncogenic signaling (p<0.05). In GIST T1 cells, exogenous KitL increased Kit activation and reduced imatinib's efficacy. Tumors from mice with homozygous KitL deletion (KitV558Δ/+;Etv1Cre-ERT2/+;KitLflox/flox) were smaller than tumors from littermates with heterozygous KitL deletion (KitV558Δ /+;Etv1Cre-ERT2/+;KitLflox/+), providing evidence that KitL contributes to GIST development in vivo despite the presence of mutated Kit (p<0.05). Furthermore, tumors from KitV558Δ/+;KitLKitL1Δ/KitL1Δ mice, which lack the proteolytic cleavage site for soluble KitL, were smaller than matched KitV558Δ/+ mice, indicating that soluble KitL is important for maximal tumor growth in vivo (p<0.05). Heterogeneous KitL expression was confirmed in human GISTs by IHC. Human serum contained more KitL in patients with tumors resistant to imatinib and in those with tumors expressing more KitL RNA(p<0.05). Conclusions: KitL is produced by multiple cell types within GIST and contributes to oncogenesis. Targeting KitL may be important for optimal tumor therapy. Citation Format: Andrew D. Tieniber, Ferdinando Rossi, Andrew Hanna, Mengyuan Liu, Mark Etherington, Kevin Do, Laura Wang, Ronald P. DeMatteo. Multiple intratumoral sources of kit ligand promote oncogenic kit signaling in gastrointestinal stomal tumor [abstract]. In: Proceedings of the AACR Special Conference: Sarcomas; 2022 May 9-12; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2022;28(18_Suppl) nr A017.

Etv1-Positive Cells Give Rise To Braf(V600e)-Mutant Gastrointestinal Stromal Tumors

Data from ETV1-Positive Cells Give Rise to <i>BRAF<sup>V600E</sup></i>-Mutant Gastrointestinal Stromal Tumors

Abstract A15: Modeling Sporadic Gastrointestinal Stromal Tumor with BRAFV600E Mutation

Altered Expression of ETV1 and Its Contribution to Tumorigenic Phenotypes in Gastrointestinal Stromal Tumors.

Figure S4 from ETV1-Positive Cells Give Rise to <i>BRAF<sup>V600E</sup></i>-Mutant Gastrointestinal Stromal Tumors

Figure S3 from ETV1-Positive Cells Give Rise to <i>BRAF<sup>V600E</sup></i>-Mutant Gastrointestinal Stromal Tumors

Figure S2 from ETV1-Positive Cells Give Rise to <i>BRAF<sup>V600E</sup></i>-Mutant Gastrointestinal Stromal Tumors

Figure S1 from ETV1-Positive Cells Give Rise to <i>BRAF<sup>V600E</sup></i>-Mutant Gastrointestinal Stromal Tumors

Figure S1-S8 from FOXF1 Defines the Core-Regulatory Circuitry in Gastrointestinal Stromal Tumor

Multiple intratumoral sources of kit ligand promote gastrointestinal stromal tumor

Genetic Aberrations Of Gastrointestinal Stromal Tumors

Abstract A017: Multiple intratumoral sources of kit ligand promote oncogenic kit signaling in gastrointestinal stomal tumor

CCBE1 promotes GIST development through enhancing angiogenesis and mediating resistance to imatinib

[Application of BRAF V600E Mutation-Specific Immunohistochemistry in Diagnosis of Gastrointestinal Stromal Tumors].

E3 ubiquitin ligase Atrogin-1 mediates adaptive resistance to KIT-targeted inhibition in gastrointestinal stromal tumor

Relationship among ETV1 Genetic Polymorphisms, PFS, and Microrna in Gastrointestinal Stromal Tumors.

RAF1 facilitates KIT signaling and serves as a potential treatment target for gastrointestinal stromal tumor

Genetic progression in gastrointestinal stromal tumors: mechanisms and molecular interventions

Clinicopathological features of BRAF V600E mutated gastrointestinal stromal tumors

[Molecular Mechanism of Gastrointestinal Stromal Tumors and Progress in Drug Research].

FOXF1 Defines the Core-Regulatory Circuitry in Gastrointestinal Stromal Tumor.